Sangamo Fabry LTFU Study Protocol ST-920-LT01

Genetics
Madeleine Pahl
Long-Term Follow-up of Fabry Disease Subjects who have Undergone IV Infusion with ST-920, an rAAV2/6 Human Alpha Galactosidase A Gene Therapy
Fabry Disease

Study Description

This is a multi-center, long-term follow-up (LTFU) study of subjects who received ST-920 in a

separate parent trial. At the final visit of parent trial, the Investigator or designated study

personnel will review the informed consent form (ICF) for this LTFU study with the study

subject. After informed consent is obtained, subjects will be followed for up to 5 years from

infusion.

Eligibility

  • Subjects who received ST-920 therapy in a separate parent trial.
  • Subjects who have consented to participate in this LTFU study.

This study does not have any exclusion criteria

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.